GINC Patents
← Capabilities
Human Capital

Physical Health & Longevity

The capacity of the population to live long lives in good physical health. One of the capabilities of Population Health.

International families
205k2015 to 2024
Leading country
United States2.4× the next
All families
665khome filings included
Over five years
Rising2020 to 2024 against the five before

Year by year

Patent families by country of origin and the year of the earliest filing, 2000 to 2025; 2025 is a part year, still filling in. International families are those for which protection was sought beyond one country.

Volume

International patent families in the capability, by the year of the earliest filing.

Source: Global Institute for National Capability (GINC), 2026. Underlying patents from 107 patent offices, IFI CLAIMS and Google

Share by country

Each country's share of the year's international families, in per cent: the capability's five largest countries of origin, 2015 to 2024, and the rest of the world.

Source: Global Institute for National Capability (GINC), 2026. Underlying patents from 107 patent offices, IFI CLAIMS and Google

Country leaderboard

International patent families, 2015 to 2024, by country of origin. Growth compares the latest five full years with the five before.

Ten largest

United States

China

South Korea

Japan

Germany

United Kingdom

Switzerland

France

India

Canada

77,497

32,383

14,190

14,101

7,671

6,453

6,355

6,297

3,766

3,596

2000 to 2025
1United States77,49737.7%1.2×
95,801
2China32,38315.8%2.2×
403,411
3South Korea14,1906.9%1.3×
42,257
4Japan14,1016.9%0.9×
28,707
5Germany7,6713.7%0.9×
8,593
6United Kingdom6,4533.1%1.0×
7,141
7Switzerland6,3553.1%1.1×
6,847
8France6,2973.1%1.0×
7,156
9India3,7661.8%1.1×
4,407
10Canada3,5961.8%1.1×
4,307
11Italy3,0811.5%1.1×
4,129
12Israel2,7181.3%1.0×
3,047
13Taiwan2,6461.3%0.8×
5,399
14Netherlands2,6391.3%1.1×
2,835
15Belgium2,1491.0%1.1×
2,373
16Spain2,1321.0%1.2×
2,521
17Australia2,0441.0%1.0×
2,375
18Denmark1,8300.9%1.0×
2,008
19Sweden1,6920.8%1.2×
1,838
20Türkiye1,6660.8%1.9×
3,233
21Singapore1,1850.6%1.5×
1,259
22Ireland1,0860.5%1.0×
1,220
23Russia8120.4%0.8×
7,310
24Poland6460.3%1.2×
2,084
25Brazil5310.3%1.0×
2,796
26Austria5230.3%1.1×
567
27Norway4560.2%0.8×
485
28Portugal3740.2%1.4×
464
29Czechia3650.2%0.7×
577
30Finland3550.2%1.0×
386
31Mexico3280.2%0.8×
1,374
32New Zealand2980.1%1.2×
377
33Hungary2300.1%1.2×
352
34Cayman Islands2240.1%0.9×
277
35Hong Kong1990.1%2.0×
430
36Luxembourg1530.1%0.4×
199
37South Africa1440.1%0.9×
156
38Saudi Arabia1380.1%0.4×
831
39Liechtenstein1230.1%1.0×
127
40Malaysia960.0%0.5×
273

Applicants

The largest applicants by international patent families, 2015 to 2024: across the world, then within each of the five countries with the most families in Physical Health & Longevity. Names are as held in the source and are not consolidated across subsidiaries.

Global

205,421 international families

UNIV CALIFORNIA · United States

INST NAT SANTE RECH MED · France

CENTRE NAT RECH SCIENT · France

HOFFMANN LA ROCHE · Switzerland

UNIV TEXAS · United States

UNIV LELAND STANFORD JUNIOR · United States

2,447

1,862

1,503

1,364

1,259

975

United States

77,497 international families

UNIV CALIFORNIA

UNIV TEXAS

UNIV LELAND STANFORD JUNIOR

UNIV JOHNS HOPKINS

US HEALTH

BRISTOL MYERS SQUIBB CO

2,394

1,210

958

740

723

700

China

32,383 international families

JIANGSU HENGRUI MEDICINE CO

MEDSHINE DISCOVERY INC

SHANGHAI INST MATERIA MEDICA CAS

JIANGSU HENGRUI PHARMACEUTICALS CO LTD

CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD

Shanghai hengrui pharmaceutical co ltd

562

500

440

392

390

376

South Korea

14,190 international families

SEOUL NAT UNIV R&DB FOUNDATION

UNIV YONSEI IACF

KOREA INST SCI & TECH

AMOREPACIFIC CORP

UNIV KOREA RES & BUS FOUND

KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY

508

378

306

303

301

215

Japan

14,101 international families

UNIV OSAKA

TAKEDA PHARMACEUTICALS CO

UNIV KYOTO

UNIV TOKYO

FUJIFILM CORP

DAIICHI SANKYO CO LTD

394

384

376

364

275

258

Germany

7,671 international families

BOEHRINGER INGELHEIM INT

BAYER AG

Bayer Pharma AG

MERCK PATENT GMBH

BioNTech SE

BASF SE

388

373

308

296

241

189

Similar capabilities

The nine capabilities that share the most international patent families with Physical Health & Longevity, 2015 to 2024: the families counted in both as a share of those counted in either. Each card shows its five largest countries.

Critical Technology

Advanced Therapeutics, Vaccines & Medical Countermeasures

34.5% shared · 72,198 families in both

United States

China

Japan

South Korea

Germany

35,382

11,223

4,471

4,072

2,767

Critical Technology

Synthetic Biology & Genetic Engineering

19.1% shared · 44,900 families in both

United States

China

Japan

South Korea

Germany

31,378

14,103

6,820

3,970

2,703

Critical Technology

Biomanufacturing

12.6% shared · 30,835 families in both

United States

China

Japan

South Korea

Germany

25,142

10,048

9,595

4,747

3,497

Human Capital

Nutrition & Preventive Health

11.2% shared · 23,739 families in both

United States

South Korea

China

Japan

Switzerland

7,952

5,251

3,446

3,403

1,203

Production & Innovation

Agrifood & Primary Production

8.1% shared · 24,942 families in both

United States

Japan

China

Germany

South Korea

28,708

17,669

15,613

10,229

9,737

Strategic Infrastructure

Chemicals & Hazardous Process Industry

4.2% shared · 11,143 families in both

United States

Japan

China

Germany

South Korea

16,120

13,036

11,408

6,357

5,716

Critical Technology

Genomics & Biological Data

3.8% shared · 9,055 families in both

United States

China

Japan

South Korea

Germany

17,818

5,444

3,003

2,851

1,616

Production & Innovation

Foundational & Process Industries

3.4% shared · 17,211 families in both

Japan

United States

China

South Korea

Germany

94,317

55,479

36,011

28,513

26,005

Human Capital

Mental Health & Wellbeing

3.2% shared · 6,860 families in both

United States

Japan

China

South Korea

Germany

5,106

2,712

1,646

1,455

591

Crosswalk

How Physical Health & Longevity is matched to the patent classifications. The entries below were chosen for it; each stands for itself and everything beneath it in the scheme, 2,155 Cooperative entries in all. A patent family counts when any of its codes, in either scheme and at any office, falls under one of them. Codes since retired are placed under the entries that replaced them.

EntryTitle in the schemeWhy it is chosenCPC codesIPC codesDocuments
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsMedicines classified by the condition they treat16417022,558,624
A61KPreparations for medical, dental or toiletry purposesMedicinal preparations of all kinds2,3691,14622,048,510
A61K8/00Cosmetics or similar toiletry preparationsLeft out
A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspectsLeft out
A61K39/002Protozoa antigensLeft out
A61K39/02Bacterial antigensLeft out
A61K39/12Viral antigensLeft out
A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophreniaLeft out
A61P25/22AnxiolyticsLeft out
A61P25/24AntidepressantsLeft out
A61P25/30Drugs for disorders of the nervous system for treating abuse or dependenceLeft out

CPC and IPC codes are the codes in use on patent documents, at any office, that fall under the entry. Documents is the larger of the two schemes' counts of documents carrying one of them. An entry with no IPC codes can be told apart only in the Cooperative scheme.

The Cooperative codes in use that count towards Physical Health & Longevity: 2,533 codes on 44,607,134 documents. The 150 most used are listed; the full list is in the cpc-to-capability.csv download.

CodeTitleUnder entryHow placedDocuments
A61P35/00Antineoplastic agentsA61PIn the scheme1,620,827
A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00A61PIn the scheme1,437,106
A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]A61PIn the scheme942,086
A61P25/00Drugs for disorders of the nervous systemA61PIn the scheme795,818
A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiacaA61KIn the scheme660,142
A61P9/00Drugs for disorders of the cardiovascular systemA61PIn the scheme624,757
A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosisA61PIn the scheme599,626
A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementiaA61PIn the scheme582,571
A61K38/00Medicinal preparations containing peptidesA61KIn the scheme537,848
A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabeticsA61PIn the scheme523,228
A61P31/04Antibacterial agentsA61PIn the scheme522,196
A61P11/00Drugs for disorders of the respiratory systemA61PIn the scheme479,612
A61P17/00Drugs for dermatological disordersA61PIn the scheme476,478
A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosisA61PIn the scheme422,644
A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectantsA61PIn the scheme372,787
A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodiesA61KIn the scheme369,886
A61P27/02Ophthalmic agentsA61PIn the scheme368,156
A61P37/00Drugs for immunological or allergic disordersA61PIn the scheme361,288
A61P1/00Drugs for disorders of the alimentary tract or the digestive systemA61PIn the scheme360,643
A61P31/12AntiviralsA61PIn the scheme358,291
A61P37/06Immunosuppressants, e.g. drugs for graft rejectionA61PIn the scheme335,744
A61P35/02Antineoplastic agents specific for leukemiaA61PIn the scheme331,922
A61P37/02ImmunomodulatorsA61PIn the scheme318,663
A61P13/12Drugs for disorders of the urinary system of the kidneysA61PIn the scheme312,522
A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeuticsA61PIn the scheme306,375
A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholyticsA61PIn the scheme300,918
A61P11/06AntiasthmaticsA61PIn the scheme300,115
A61P3/00Drugs for disorders of the metabolismA61PIn the scheme286,066
A61P37/08Antiallergic agentsA61PIn the scheme285,275
A61P9/12AntihypertensivesA61PIn the scheme278,956
A61P3/04Anorexiants; Antiobesity agentsA61PIn the scheme275,860
A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive mannerA61KIn the scheme263,694
A61P17/06AntipsoriaticsA61PIn the scheme263,553
A61P25/04Centrally acting analgesics, e.g. opioidsA61PIn the scheme257,118
A61P25/16Anti-Parkinson drugsA61PIn the scheme243,759
A61P15/00Drugs for genital or sexual disorders; ContraceptivesA61PIn the scheme241,240
A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the likeA61PIn the scheme233,148
A61P3/06AntihyperlipidemicsA61PIn the scheme221,571
A61P37/04ImmunostimulantsA61PIn the scheme219,384
A61P21/00Drugs for disorders of the muscular or neuromuscular systemA61PIn the scheme206,324
A61P7/00Drugs for disorders of the blood or the extracellular fluidA61PIn the scheme202,399
A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00A61KIn the scheme201,586
A61P31/18Antivirals for RNA viruses for HIVA61PIn the scheme191,944
A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitorsA61PIn the scheme188,045
A61P35/04Antineoplastic agents specific for metastasisA61PIn the scheme171,881
A61P31/14Antivirals for RNA virusesA61PIn the scheme166,703
A61P19/00Drugs for skeletal disordersA61PIn the scheme165,240
A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic ringsA61KIn the scheme161,114
A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethersA61KIn the scheme157,468
A61P25/08Antiepileptics; AnticonvulsantsA61PIn the scheme155,403
A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesiaA61PIn the scheme152,643
A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failureA61PIn the scheme151,184
A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosisA61PIn the scheme149,855
A61K9/0014Skin, i.e. galenical aspects of topical compositionsA61KIn the scheme147,493
A61P25/02Drugs for disorders of the nervous system for peripheral neuropathiesA61PIn the scheme143,184
A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serumA61KIn the scheme140,787
A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizinA61KIn the scheme139,356
A61P25/20Hypnotics; SedativesA61PIn the scheme138,359
A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapyA61KIn the scheme137,869
A61K39/00Medicinal preparations containing antigens or antibodiesA61KIn the scheme132,546
A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's diseaseA61PIn the scheme132,400
A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic ringsA61KIn the scheme132,214
A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timololA61KIn the scheme129,889
A61K9/08SolutionsA61KIn the scheme126,439
A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administrationA61KIn the scheme124,130
A61P31/10AntimycoticsA61PIn the scheme120,899
A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacinA61KIn the scheme116,080
A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokinesA61KIn the scheme115,003
A61P25/06Antimigraine agentsA61PIn the scheme112,190
A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitisA61PIn the scheme111,393
A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazoleA61KIn the scheme109,388
A61P7/06AntianaemicsA61PIn the scheme107,102
A61K47/02Inorganic compoundsA61KIn the scheme105,905
A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiersA61PIn the scheme101,403
A61P11/02Nasal agents, e.g. decongestantsA61PIn the scheme98,648
A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcelluloseA61KIn the scheme98,366
A61P27/06Antiglaucoma agents or mioticsA61PIn the scheme95,487
A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymesA61PIn the scheme95,091
A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agentsA61PIn the scheme92,837
A61P13/08Drugs for disorders of the urinary system of the prostateA61PIn the scheme92,821
A61P9/08Vasodilators for multiple indicationsA61PIn the scheme92,488
A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gelsA61KIn the scheme91,752
A61K47/12Carboxylic acids; Salts or anhydrides thereofA61KIn the scheme90,462
A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration scheduleA61KIn the scheme88,876
A61P33/00Antiparasitic agentsA61PIn the scheme87,968
A61K36/185Magnoliopsida (dicotyledons)A61KIn the scheme86,821
A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cellsA61KIn the scheme85,541
A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravisA61PIn the scheme85,129
A61P5/00Drugs for disorders of the endocrine systemA61PIn the scheme84,762
A61K31/00Medicinal preparations containing organic active ingredientsA61KIn the scheme84,457
A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carbolineA61KIn the scheme84,110
A61P17/04AntipruriticsA61PIn the scheme83,955
A61P31/20Antivirals for DNA virusesA61PIn the scheme83,620
A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectinA61KIn the scheme83,007
A61P31/16Antivirals for RNA viruses for influenza or rhinovirusesA61PIn the scheme82,048
A61P13/00Drugs for disorders of the urinary systemA61PIn the scheme79,548
A61P9/06AntiarrhythmicsA61PIn the scheme78,484
A61K31/44Non condensed pyridines; Hydrogenated derivatives thereofA61KIn the scheme77,818
A61P27/16OtologicalsA61PIn the scheme76,485
A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesisA61PIn the scheme76,243
A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazoleA61KIn the scheme75,311
A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulentsA61PIn the scheme74,575
A61P17/14Drugs for dermatological disorders for baldness or alopeciaA61PIn the scheme73,008
A61P3/08Drugs for disorders of the metabolism for glucose homeostasisA61PIn the scheme72,753
A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenchesA61KIn the scheme71,313
A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvantsA61KIn the scheme70,983
A61K9/20Pills, tablets, discs, rodsA61KIn the scheme70,777
A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidoneA61KIn the scheme70,619
A61K47/38Cellulose; Derivatives thereofA61KIn the scheme70,419
A61P11/08BronchodilatorsA61PIn the scheme70,402
A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedilA61KIn the scheme69,833
A61P3/02Nutrients, e.g. vitamins, mineralsA61PIn the scheme69,626
A61P13/10Drugs for disorders of the urinary system of the bladderA61PIn the scheme68,053
A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]A61KIn the scheme68,042
A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid estersA61KIn the scheme68,029
A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersionsA61KIn the scheme67,610
A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamersA61KIn the scheme67,519
A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbatesA61KIn the scheme67,001
A61K9/0048Eye, e.g. artificial tearsA61KIn the scheme66,978
A61P31/22Antivirals for DNA viruses for herpes virusesA61PIn the scheme65,272
A61K31/445Non condensed piperidines, e.g. piperocaineA61KIn the scheme62,828
A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoctionA61KIn the scheme61,935
A61P1/12AntidiarrhoealsA61PIn the scheme61,678
A61P21/02Muscle relaxants, e.g. for tetanus or crampsA61PIn the scheme61,239
A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotenceA61PIn the scheme61,225
A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerolA61KIn the scheme60,317
A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigensA61KIn the scheme59,978
A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; CyclodextrinA61KIn the scheme59,027
A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidoneA61KIn the scheme58,902
A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisersA61PIn the scheme58,664
A61K31/7088Compounds having three or more nucleosides or nucleotidesA61KIn the scheme58,635
A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprimA61KIn the scheme58,630
A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammalsA61KIn the scheme58,374
A61K31/713Double-stranded nucleic acids or oligonucleotidesA61KIn the scheme57,643
A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxinA61KIn the scheme56,829
A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animalsA61KIn the scheme56,665
A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4A61PIn the scheme56,078
A61P17/10Anti-acne agentsA61PIn the scheme55,883
A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidonesA61KIn the scheme55,718
A61K47/183Amino acids, e.g. glycine, EDTA or aspartameA61KIn the scheme55,653
A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; AntiemeticsA61PIn the scheme55,099
A61P39/06Free radical scavengers or antioxidantsA61PIn the scheme55,052
A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid deliveredA61KIn the scheme55,022
A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidineA61KIn the scheme54,794
A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasineA61KIn the scheme54,784
A61K31/47Quinolines; IsoquinolinesA61KIn the scheme54,763
A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinoneA61KIn the scheme54,692
A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadoneA61KIn the scheme54,623
A61K31/19Carboxylic acids, e.g. valproic acidA61KIn the scheme54,520
A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactantA61KIn the scheme54,470
Match: Through its tools
The classification names the equipment or technology the capability draws on, not the capability. The count says how much is being invented for it, not how well it is done. Captures medicines for physical disease; cosmetics, vaccines and psychiatric and dependence drugs are excluded and the last two are counted under the sibling capabilities. The crosswalk is a first pass that nobody has reviewed.

Other capabilities in Population Health